Atossa Therapeutics Inc ATOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATOS is a good fit for your portfolio.
News
-
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
-
Thinking about buying stock in Pixelworks, Backblaze, Praxis Precision Medicines, Scworx, or Atossa Therapeutics?
-
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
-
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
-
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
-
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
-
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
-
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Trading Information
- Previous Close Price
- $1.83
- Day Range
- $1.76–1.91
- 52-Week Range
- $0.59–1.94
- Bid/Ask
- $1.80 / $1.83
- Market Cap
- $225.55 Mil
- Volume/Avg
- 1.9 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.66%
Company Profile
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
Comparables
Valuation
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.30 | 0.86 | 0.61 |
Price/Sales | — | 34.40 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ATOS
VIR
AVIR
Financial Strength
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Quick Ratio | 27.31 | 8.68 | 17.86 |
Current Ratio | 28.35 | 9.05 | 18.24 |
Interest Coverage | — | — | — |
Quick Ratio
ATOS
VIR
AVIR
Profitability
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −18.38% | −20.03% | −15.46% |
Return on Equity (Normalized) | −19.08% | −25.63% | −16.16% |
Return on Invested Capital (Normalized) | −22.37% | −28.31% | −19.92% |
Return on Assets
ATOS
VIR
AVIR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Csktslhplb | Fskkk | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zqmpzvdcl | Zgmwyfx | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vlyqxkpzl | Mmdtkv | $105.6 Bil | |
MRNA
| Moderna Inc | Vbbgtprvw | Ndcf | $40.8 Bil | |
ARGX
| argenx SE ADR | Xrrhzyqtm | Nzlf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Hzkngjdxy | Hsbp | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vhsrdtbxm | Tnzxndd | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ljjndtld | Gdmbs | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zkchdvqfqk | Lpnfm | $13.6 Bil | |
INCY
| Incyte Corp | Txgqkqkt | Kdtky | $12.8 Bil |